Kobo Biotech Ltd
- Market Cap ₹ 6.17 Cr.
- Current Price ₹ 2.59
- High / Low ₹ 3.58 / 1.99
- Stock P/E
- Book Value ₹ 23.6
- Dividend Yield 0.00 %
- ROCE -4.43 %
- ROE -65.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.11 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -27.2% over last 3 years.
- Company has high debtors of 671 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| 162 | 287 | 404 | 103 | 103 | |
| 133 | 238 | 361 | 104 | 104 | |
| Operating Profit | 29 | 49 | 43 | -1 | -1 |
| OPM % | 18% | 17% | 11% | -1% | -1% |
| 0 | 0 | 0 | 0 | 0 | |
| Interest | 13 | 21 | 18 | 24 | 24 |
| Depreciation | 6 | 11 | 10 | 10 | 10 |
| Profit before tax | 10 | 18 | 15 | -34 | -34 |
| Tax % | 0% | 11% | 8% | 2% | 2% |
| 10 | 16 | 14 | -35 | -35 | |
| EPS in Rs | 4.37 | 6.72 | 6.22 | -15.48 | -15.48 |
| Dividend Payout % | 23% | 15% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -29% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -21% |
| 5 Years: | -15% |
| 3 Years: | 7% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -27% |
| Last Year: | -66% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 |
| Reserves | 39 | 51 | 65 | 31 | 31 |
| 131 | 118 | 182 | 179 | 179 | |
| 57 | 154 | 142 | 163 | 163 | |
| Total Liabilities | 250 | 346 | 412 | 396 | 396 |
| 110 | 100 | 108 | 104 | 104 | |
| CWIP | 0 | 13 | 3 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 140 | 232 | 301 | 290 | 290 | |
| Total Assets | 250 | 346 | 412 | 396 | 396 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| 64 | 37 | 7 | 7 | ||
| -14 | -7 | -5 | -5 | ||
| -27 | -38 | -13 | -13 | ||
| Net Cash Flow | 23 | -9 | -11 | -11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| Debtor Days | 143 | 187 | 185 | 671 | 671 |
| Inventory Days | 179 | 79 | 66 | 300 | 300 |
| Days Payable | 115 | 203 | 111 | 468 | 468 |
| Cash Conversion Cycle | 207 | 62 | 140 | 503 | 503 |
| Working Capital Days | 88 | 28 | 25 | 98 | 73 |
| ROCE % | 20% | 14% | -4% | -4% |
Insights
In beta| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Production and Operational Activity Status Status (1=Active, 0=Suspended) ・Standalone data |
|
||||||||||
| Revenue from Operations (Sales of API / Intermediates / Contract Mfg) INR ・Standalone data |
|||||||||||
| Employee Benefit Expenses INR Lakhs ・Standalone data |
|||||||||||
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Feb
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Feb - RTA certificate confirming compliance under SEBI Regulation 74(5) for quarter ended September 30, 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Feb - RTA certificate confirming compliance under SEBI Reg 74(5) for quarter ended 31-Dec-2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Feb - Certificate under SEBI Regulation 74(5) for quarter ended 31 March 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Feb - RTA certificate confirming dematerialisation compliance under Reg 74(5) for quarter ended 31 December 2025.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
KBL manufactures Active Pharmaceutical Ingredients based on Fermentation technology. Its manufacturing facility is located in Solapur, Maharashtra, spread over 21 acres